Litcius/Paper detail

Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study

Christian Pfister, Gwénaëlle Gravis, Aude Fléchon, Christine Chevreau, Hakim Mahammedi, Brigitte Laguerre, Aline Guillot, Florence Joly, M. Soulié, Yves Allory, Valentin Harter, Stéphane Culine, G. Pignot, J.P. Fendler, Laurent Guy, G. Verhoest, Nicolas Mottet, A. Doerfler, Sophie Abadie Lacourtoisie, A.R. Azzouzi, P. Mongiat, Lionnel Geoffrois, Pascal Eschwège, Frédéric Di Fiore, Guilhem Roubaud, J.L. Hoepffner, Philippe Barthélémy, Hervé Lang, Éric Voog, E. Mandron, Jean Marc Tourani, Camille Serrate, A. Colau, Carolina Saldana, Alexandre de la Taille, Thi Hong Lieu Nguyen, F. Kleinclauss, Yohan LORIOT, Jacques Irani, J.C. Eymard, S. Larré, Olivier Huillard, Marc Zerbib, Frédéric Rolland, J. Rigaud, Nadine Houédé, S. Droupy, Georgina MALOUF, Morgan Rouprêt, S. Vieillot, N. Letang, T. L'Haridon, N. Gaschignard, Werner Hilgers, Jean Louis DAVIN

2023The Lancet Oncology96 citationsDOI

Topics & Concepts

MedicineBladder cancerVinblastineUrologyPerioperativeCystectomyInternal medicineCancerHazard ratioSurgeryOncologyChemotherapyConfidence intervalBladder and Urothelial Cancer TreatmentsMultiple and Secondary Primary CancersUrinary and Genital Oncology Studies
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study | Litcius